JPRN-UMIN000006134已完成4 期
Pilot study of FOLFOX or XELOX Therapy Versus FOLFOX or XELOX + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colon Cancer - Pilot study of FOLFOX or XELOX + PSK Therapy as Postoperative Adjuvant Therapy for Stage III Colon Cancer
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patient with metachronous or synchronous cancer 2.Patient who requires continuous use of phenytoin or warfarin potassium 3.Patient who has experienced serious drug allergy over grade 3 in the past 4.Patient with serious complications including paralysis of intestine, ileus, interstitial pneumonitis, fibroid lung, uncontrollable diabetes mellitus, heart insufficiency, renal insufficiency or hepatic insufficiency 5.Patient who is pregnant or in lactation, or wish to become pregnant during this study 6.Male patient who intends to make someone pregnant during this study 7.Patient with HIV positive 8.Patient who is judged to be inappropriate as subject to this study by the principal investigator or the doctors in charge
研究者
相似试验
已完成
2 期
Evaluation of the reintroducing FOLFOX or XELOX +/- BV in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy.(REACT study)Colorectal CancerJPRN-UMIN000006523Hyogo College of Medicine, Department of Surgery30
尚未招募
2 期
Evaluation of preferred chemotherapy regimen during esophageal cancer radiotherapyesophageal cancer.Malignant neoplasm of esophagusIRCT20240701062297N1Tehran University of Medical Sciences98
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-CZPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
进行中（未招募）
不适用
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-BEPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176
进行中（未招募）
1 期
Randomized, Phase 2 Study of FOLFOX or FOLFIRI with AG-013736 or Bevacizumab in Patients with Metastatic Colorectal Cancer after Failure of an Irinotecan or Oxaliplatin-containing First-line RegimeSecond line treatment of patients with metastatic carcinoma of colon and rectumMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerMedDRA version: 9.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2007-006283-30-FRPfizer Inc, 235 East 42nd Street, New York, NY 10017, USA176